bluebird bio Inc (NAS:BLUE)
$ 0.405 0.0272 (7.2%) Market Cap: 78.75 Mil Enterprise Value: 376.50 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

bluebird bio Inc at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 11:00PM GMT
Release Date Price: $59.61 (+6.29%)
Cory William Kasimov
JP Morgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good afternoon, everyone. My name is Cory Kasimov, a senior biotech analyst at JPMorgan, and it's my pleasure to introduce our next company, bluebird bio. Here to present for the company is the Chief bluebird himself, Nick Leschly. And please note that following Nick's presentation, there's a breakout just across the hall in the Georgian Room.

So with that, I'll turn it over to Nick.

Nick Leschly
bluebird bio, Inc. - President, CEO & Director

Thank you, Cory, and -- for that title introduction. I appreciate it. And thank you, everybody, for coming and JPMorgan for having me have the opportunity to represent bluebird and represent all the people that are here that are bluebirds also who are listening or who've been part of everything I'm about to describe. It really is an honor and a pleasure. And also thank you for all of you coming in. I know everyone has a lot of different choices and where they can go and how they can show up.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot